8-K current report · filed Oct 20, 2026

Inhibikase Therapeutics, Inc. (IKT) 8-K Current Report: October 20, 2026

Item 5.02Item 7.01Item EX-99.1IKT overview

Short answer

Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Dennis Berman resigned as director and Compensation Committee Chair on October 19, 2026.

Inhibikase Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Dennis Berman resigned as director and Compensation Committee Chair on October 19, 2026
  • Scott Wasserman appointed independent Class III director through 2029 annual meeting
  • Wasserman joins Compensation Committee, preserving committee coverage after Berman’s departure
  • 310,000 non-qualified stock options plus cash director compensation, creating shareholder dilution potential
  • No disclosed disagreements, related-party transactions, or selection arrangements involving Wasserman

Item 7.01 · Regulation FD Disclosure

  • Scott Wasserman appointed to Inhibikase Therapeutics’ board of directors
  • Board appointment may influence governance, strategic oversight and shareholder confidence
  • Press release dated October 20, 2026, provides the substantive appointment details

Item EX-99.1 · Exhibit EX-99.1

  • Scott Wasserman appointed director effective October 19, 2026, replacing departing director Dennis Berman
  • Experienced cardiovascular and metabolic drug developer, including leadership of Repatha, Evenity and Aimovig programs
  • Appointment strengthens board expertise for global Phase 3 IMPROVE-PAH study of once-daily IKT-001
  • IMPROVE-PAH actively enrolling across approximately 180 sites worldwide
  • Clinical and regulatory execution remain key risks, with no change to IKT-001’s development status disclosed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inhibikase Therapeutics, Inc. 8-K filings

Get the next IKT 8-K as it lands

Follow IKT for push alerts, or ask the research agent what this filing means.